These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 16914579)

  • 1. CHIR-258 is efficacious in a newly developed fibroblast growth factor receptor 3-expressing orthotopic multiple myeloma model in mice.
    Xin X; Abrams TJ; Hollenbach PW; Rendahl KG; Tang Y; Oei YA; Embry MG; Swinarski DE; Garrett EN; Pryer NK; Trudel S; Jallal B; Mendel DB; Heise CC
    Clin Cancer Res; 2006 Aug; 12(16):4908-15. PubMed ID: 16914579
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma.
    Trudel S; Li ZH; Wei E; Wiesmann M; Chang H; Chen C; Reece D; Heise C; Stewart AK
    Blood; 2005 Apr; 105(7):2941-8. PubMed ID: 15598814
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo target modulation and biological activity of CHIR-258, a multitargeted growth factor receptor kinase inhibitor, in colon cancer models.
    Lee SH; Lopes de Menezes D; Vora J; Harris A; Ye H; Nordahl L; Garrett E; Samara E; Aukerman SL; Gelb AB; Heise C
    Clin Cancer Res; 2005 May; 11(10):3633-41. PubMed ID: 15897558
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deregulated FGFR3 mutants in multiple myeloma cell lines with t(4;14): comparative analysis of Y373C, K650E and the novel G384D mutations.
    Ronchetti D; Greco A; Compasso S; Colombo G; Dell'Era P; Otsuki T; Lombardi L; Neri A
    Oncogene; 2001 Jun; 20(27):3553-62. PubMed ID: 11429702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bortezomib therapeutic effect is associated with expression of FGFR3 in multiple myeloma cells.
    Guan M; Zhu L; Somlo G; Hughes A; Zhou B; Yen Y
    Anticancer Res; 2009 Jan; 29(1):1-9. PubMed ID: 19331127
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection and follow-up of fibroblast growth factor receptor 3 expression on bone marrow and circulating plasma cells by flow cytometry in patients with t(4;14) multiple myeloma.
    Chandesris MO; Soulier J; Labaume S; Crinquette A; Repellini L; Chemin K; Malphettes M; Fieschi C; Asli B; Uzunhan Y; Fermand JP; Bories JC; Arnulf B
    Br J Haematol; 2007 Feb; 136(4):609-14. PubMed ID: 17223917
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor.
    Yeh TC; Marsh V; Bernat BA; Ballard J; Colwell H; Evans RJ; Parry J; Smith D; Brandhuber BJ; Gross S; Marlow A; Hurley B; Lyssikatos J; Lee PA; Winkler JD; Koch K; Wallace E
    Clin Cancer Res; 2007 Mar; 13(5):1576-83. PubMed ID: 17332304
    [TBL] [Abstract][Full Text] [Related]  

  • 8. p38alpha-selective MAP kinase inhibitor reduces tumor growth in mouse xenograft models of multiple myeloma.
    Medicherla S; Reddy M; Ying J; Navas TA; Li L; Nguyen AN; Kerr I; Hanjarappa N; Protter AA; Higgins LS
    Anticancer Res; 2008; 28(6A):3827-33. PubMed ID: 19189670
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical activity of a novel multiple tyrosine kinase and aurora kinase inhibitor, ENMD-2076, against multiple myeloma.
    Wang X; Sinn AL; Pollok K; Sandusky G; Zhang S; Chen L; Liang J; Crean CD; Suvannasankha A; Abonour R; Sidor C; Bray MR; Farag SS
    Br J Haematol; 2010 Aug; 150(3):313-25. PubMed ID: 20560971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bortezomib, dexamethasone, and fibroblast growth factor receptor 3-specific tyrosine kinase inhibitor in t(4;14) myeloma.
    Bisping G; Wenning D; Kropff M; Gustavus D; Müller-Tidow C; Stelljes M; Munzert G; Hilberg F; Roth GJ; Stefanic M; Volpert S; Mesters RM; Berdel WE; Kienast J
    Clin Cancer Res; 2009 Jan; 15(2):520-31. PubMed ID: 19147757
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical studies of fibroblast growth factor receptor 3 as a therapeutic target in multiple myeloma.
    Paterson JL; Li Z; Wen XY; Masih-Khan E; Chang H; Pollett JB; Trudel S; Stewart AK
    Br J Haematol; 2004 Mar; 124(5):595-603. PubMed ID: 14871245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Down-regulation of insulin-like growth factor I receptor activity by NVP-AEW541 has an antitumor effect on neuroblastoma cells in vitro and in vivo.
    Tanno B; Mancini C; Vitali R; Mancuso M; McDowell HP; Dominici C; Raschellà G
    Clin Cancer Res; 2006 Nov; 12(22):6772-80. PubMed ID: 17121898
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Semaphorin SEMA3F affects multiple signaling pathways in lung cancer cells.
    Potiron VA; Sharma G; Nasarre P; Clarhaut JA; Augustin HG; Gemmill RM; Roche J; Drabkin HA
    Cancer Res; 2007 Sep; 67(18):8708-15. PubMed ID: 17875711
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo.
    Hideshima T; Neri P; Tassone P; Yasui H; Ishitsuka K; Raje N; Chauhan D; Podar K; Mitsiades C; Dang L; Munshi N; Richardson P; Schenkein D; Anderson KC
    Clin Cancer Res; 2006 Oct; 12(19):5887-94. PubMed ID: 17020997
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice.
    Qing J; Du X; Chen Y; Chan P; Li H; Wu P; Marsters S; Stawicki S; Tien J; Totpal K; Ross S; Stinson S; Dornan D; French D; Wang QR; Stephan JP; Wu Y; Wiesmann C; Ashkenazi A
    J Clin Invest; 2009 May; 119(5):1216-29. PubMed ID: 19381019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.
    McMillin DW; Ooi M; Delmore J; Negri J; Hayden P; Mitsiades N; Jakubikova J; Maira SM; Garcia-Echeverria C; Schlossman R; Munshi NC; Richardson PG; Anderson KC; Mitsiades CS
    Cancer Res; 2009 Jul; 69(14):5835-42. PubMed ID: 19584292
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Monoclonal antibody against brain derived neurotrophic factor inhibits myeloma growth and angiogenesis in the xenograft NOD/SCID animal model].
    Wang YD; Hu Y; Zhang L; Huang J; Sun CY
    Zhonghua Xue Ye Xue Za Zhi; 2007 Oct; 28(10):659-63. PubMed ID: 18399169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel ginseng saponin metabolite induces apoptosis and down-regulates fibroblast growth factor receptor 3 in myeloma cells.
    Choi HH; Jong HS; Park JH; Choi S; Lee JW; Kim TY; Otsuki T; Namba M; Bang YJ
    Int J Oncol; 2003 Oct; 23(4):1087-93. PubMed ID: 12963989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical pharmacokinetics of MFGR1877A, a human monoclonal antibody to FGFR3, and prediction of its efficacious clinical dose for the treatment of t(4;14)-positive multiple myeloma.
    Kamath AV; Lu D; Gupta P; Jin D; Xin Y; Brady A; Stephan JP; Li H; Tien J; Qing J; Damico-Beyer LA
    Cancer Chemother Pharmacol; 2012 Apr; 69(4):1071-8. PubMed ID: 22203368
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting FGFR3 in multiple myeloma: inhibition of t(4;14)-positive cells by SU5402 and PD173074.
    Grand EK; Chase AJ; Heath C; Rahemtulla A; Cross NC
    Leukemia; 2004 May; 18(5):962-6. PubMed ID: 15029211
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.